Cathie Wood’s September Bet: Why ARK is Dumping Biotech to Chase Meta and Space Infrastructure

Posted on by

(SeaPRwire) –   By: Oliver Hawthorne

The market loves a tidy narrative, but portfolio rebalancing is usually an exercise in brutal pragmatism. When a high-profile fund manager starts slashing positions in specialized genomics while aggressively pouring tens of millions into mega-cap platforms and aerospace infrastructure, it signals a deeper recalibration of risk. Growth investors are currently grappling with severe valuation compression and sector fatigue, forcing them to concentrate capital where cash flows and operational scale offer immediate defensive shelter against macroeconomic headwinds.

The transaction data from Friday, September 11, 2026, details a sweeping tactical retreat from specific biotech and diagnostics names alongside targeted capital deployment into artificial intelligence and deep tech. ARK shed 46,015 shares of Twist Bioscience through its ARKK ETF, netting roughly $5.8 million, following weeks of steady position trimming. Additional liquidations included 60,556 shares of 10X Genomics for $4 million, 121,217 shares of Bullish for $4.1 million, and smaller exits in Tempus AI, GeneDx Holdings, and Alphabet. Conversely, the firm accumulated nearly 115,000 shares of Intellia Therapeutics for $1.4 million. More aggressively, two ARK funds scooped up $27.9 million of Meta Platforms stock on September 9 while shares hovered 18% below their peak. Between August 31 and September 8, three ARK ETFs also piled roughly $45 million into Rocket Lab as its equity slid nearly 60% from earlier highs.

Beneath these shifting portfolio weights lies a calculated wager on platform dominance and physical network scarcity. Meta leverages an active base of 3.6 billion daily users, applying advanced machine learning to optimize ad targeting and drive a 28% year-over-year second-quarter revenue jump, backed by an eye-watering capital expenditure plan for 2026. Meanwhile, Rocket Lab boasts a record $2.36 billion backlog, extreme launch demand stretching past 2029, and strategic satellite acquisitions like Iridium. As the flagship ARKK fund limps along with a modest 9% gain in 2026, this reallocation exposes the ultimate industry end-game: speculative early-stage bets are taking a backseat to cash-generative digital monoliths and irreplaceable industrial space monopolies.

Author bio: Oliver Hawthorne, a Principal Correspondent permanently stationed at an international technology review, specializing in the intersection of public equity markets, venture capital allocations, and deep-tech scaling strategies.